Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
Fu S et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2025
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung Cancer.
Mathiot L et al.
Clinical Lung Cancer, 2024
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
37922692 (PubMed )
Supplement: mmc1.docx
The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
Nasioudis D et al.
Gynecologic Oncology, 2023
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.
Szlosarek PW et al.
Cancer Medicine, 2021
Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience.
Burns EA et al.
Journal of Thoracic Disease, 2021
Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer.
Shen M et al.
Frontiers in Oncology, 2021
Select a paper to view details